Liraglutide Reduced Stroke Recurrence by 12.3% in Insulin-Resistant Type 2 Diabetes Patients
Background
Type 2 diabetes (T2D) significantly increases the risk of major adverse cardiovascular events (MACE), including stroke. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated efficacy in reducing MACE in T2D patients. However, it remains unclear whether insulin resistance (IR), a common comorbidity in T2D, influences the therapeutic benefits of GLP-1RA treatment. Current understanding suggests that body mass index (BMI) does not modify these effects, highlighting a critical gap in identifying specific patient subgroups that might derive the most benefit from GLP-1RA therapy for stroke prevention.
Study Design
This post hoc analysis of the LAMP trial, a multicenter, open-label, randomized controlled trial, included 510 patients with minor ischemic stroke or high-risk transient ischemic attack (TIA) and type 2 diabetes. Participants were randomized (1:1) to receive liraglutide plus standard therapy or standard therapy alone. Insulin resistance was assessed via homeostasis model assessment of IR (HOMA-IR), using a cutoff of 2.5 established in Asian populations. Treatment-by-IR interactions were evaluated using Cox models.
Results
Among the 510 patients analyzed (mean age 65 years, 64.7% male, 3 months follow-up), a significant interaction between liraglutide treatment and insulin resistance was observed for both stroke recurrence and composite vascular events (P for interaction=0.02 for both outcomes). > In patients with HOMA-IR ≥2.5, liraglutide significantly reduced stroke recurrence from 18.1% to 5.8%, representing an absolute risk reduction (ARR) of 12.3% (95% CI, 5.6%-19.0%; NNT=8). Similarly, composite vascular events were reduced from 19.2% to 5.8% (ARR 13.4% [95% CI, 6.6%-20.2%]; NNT=8) in this insulin-resistant subgroup. No significant benefit was observed in patients with HOMA-IR <2.5.
Why It Matters
This analysis highlights insulin resistance as a crucial biomarker for predicting liraglutide's efficacy in preventing recurrent stroke and vascular events in type 2 diabetes patients. For clinicians and biohackers, this suggests that screening for high HOMA-IR could identify a subgroup of patients who would derive substantial benefit from GLP-1RA therapy. This finding refines the understanding of GLP-1RA responders, moving towards more personalized medicine. While this is a post hoc analysis, the significant interaction effect warrants further prospective studies. Integrating HOMA-IR assessment into clinical protocols could optimize liraglutide prescribing for secondary stroke prevention.